A New Wave of Innovation in Neovascular Eye Disease

Paul Chaney
PRESIDENT AND CHIEF EXECUTIVE OFFICER

Paul Chaney is president and CEO of PanOptica and has nearly 30 years of experience in the pharmaceutical industry. He was responsible for Xalatan, the most widely prescribed treatment for elevated intraocular pressure (glaucoma) and the first pharmacotherapy for neovascular AMD.

Prior to co-founding PanOptica, Paul was executive vice president of OSI Pharmaceuticals and president of (OSI) Eyetech, OSI’s eyecare subsidiary. He joined Eyetech Pharmaceuticals as chief operating officer in 2003.

Paul held a variety of senior management positions at Pharmacia Corporation, including vice president of the Global Ophthalmology Business and vice president of Global Pharmaceutical Ophthalmology. He began his career as a sales representative for The Upjohn Company in 1980. Paul earned a dual degree in Biological Sciences and English from the University of Delaware.

Martin Wax, M.D.
CHIEF MEDICAL OFFICER AND EXECUTIVE VICE-PRESIDENT OF RESEARCH AND DEVELOPMENT

Martin B. Wax, M.D., is chief medical officer and executive vice president of research and development at PanOptica, and a Clinical Professor of Ophthalmology at the NYU Langone Medical Center in New York City. He previously served as vice president of R&D and head of discovery research and preclinical sciences at Alcon Laboratories, where he was responsible for the creation and early development of the Alcon pharmaceutical portfolio. Dr. Wax received his medical degree from the University of Southern California in Los Angeles. He completed his residency in Ophthalmology at Wills Eye Hospital in Pennsylvania, and post-doctoral fellowships in molecular pharmacology and glaucoma at the University of Pennsylvania School of Medicine. He currently holds an appointment as a Professor of Ophthalmology and Visual Sciences at the University of Texas Southwestern Medical School in Dallas, and has been selected as one of the “Best Doctors in America” by his peers. An internationally recognized scientific expert in the field of glaucoma, Dr. Wax has co-authored more than 200 publications and serves on several scientific advisory committees and editorial boards.

Here is a link to Dr. Wax’s CV.

Lori Forrest
EXECUTIVE DIRECTOR OF FINANCE AND CONTROLLER

Lori Forrest is the executive director of finance and controller at PanOptica. She has over 20 years of accounting experience in the pharmaceutical and consumer products industries. Her responsibilities have included financial reporting (including SEC reporting requirements and compliance with the Sarbanes-Oxley Act of 2002), budgets and forecasts, and human resource and information technology functions. Most recently, Lori was the Controller at Helsinn Therapeutics, Inc. (previously Sapphire Therapeutics, Inc.), where she played a key role in the due-diligence, merger and post-acquisition integration activities when Sapphire was purchased in January 2009. From 1997-2005, Lori worked at Vivus, Inc. in roles of increasing responsibility in both operations and corporate finance. She began her career at Carter-Wallace, Inc. after graduating from Cook College, Rutgers University with a Bachelor of Science degree in Business Economics. Lori is a certified public accountant.

David P. Bingaman, DVM, Ph.D.
SENIOR DIRECTOR OF CLINICAL DEVELOPMENT

As senior director of clinical development at PanOptica, David Bingham, DVM, Ph.D., is responsible for managing PanOptica’s Retina programs, including PAN-90806, the company’s lead therapeutic candidate. David previously spent 13 years at Alcon Laboratories in Ft. Worth, Texas, where he established Ocular Angiogenesis and Diabetic Retinopathy programs, directed various aspects within Retina Development, and received the Alcon Technical Excellence Award in 2006. Dr. Bingaman earned his veterinary medical degree from Washington State University and completed an internship and residency in veterinary ophthalmology at Purdue University. He conducted his doctoral thesis in pathologic ocular angiogenesis and diabetic retinopathy in a combined program at Purdue University/Indiana University. Dr. Bingaman is a board-certified veterinary ophthalmologist and Diplomate of the American College of Veterinary Ophthalmologists.

Kristine Curtiss
EXECUTIVE DIRECTOR OF CLINICAL OPERATIONS

As executive director of clinical operations for PanOptica, Kristine Curtiss brings 20 years of experience in the pharmaceutical, biotechnology, and medical device industries. Previously, Kristine managed all phases of global clinical trials on strategic programs in neurology and oncology at Hoffman La-Roche, Inc. Her work there led to the approval of Tasmar® (tolcapone) and Xeloda® (capecitabine) in the United States and in Europe. Kristine also served as executive director of clinical research at Eyetech Pharmaceuticals, where she was responsible for implementing and directing the clinical program leading to the U.S. and European approvals of Macugen® (pegaptanib sodium) for neovascular age-related macular degeneration. Previously, she was director of global ophthalmology programs at Opko Health and Oraya Therapeutics, Inc. Kristine holds a Bachelor of Science degree in Chemistry from the University of Delaware.

Angela C. Kothe, O.D., PhD
CLINICAL AND REGULATORY AFFAIRS CONSULTANT

Angela C. Kothe is Vice President of Silver Pharma Consulting, Inc., a firm providing clinical development, medical safety, and regulatory consulting expertise to a variety of domestic and international ophthalmology clients. Angela brings 25 years of experience in the pharmaceutical, biotechnology and medical device industry. Prior to consulting, Angela spent 19 years at Alcon Laboratories, Inc. She began her pharmaceutical career in 1993 managing clinical trials at Alcon, and in 2000, transitioned to regulatory affairs at Alcon. Her leadership in regulatory affairs led to the approval of key anti-infective, anti-inflammatory, ocular allergy and glaucoma products in the US and internationally. During the past five years, she has provided regulatory expertise to ophthalmic companies in the areas of ocular allergy, glaucoma, inflammation, retina, and dry eye. She has led several companies through the IND and NDA process, provided regulatory strategies and managed operational activities, and led meetings with the FDA and international health agencies.
Angela holds a Bachelor of Science (Life Sciences) from Queen’s University, Kingston, Ontario, Canada, and a Doctor of Optometry and PhD in visual electrophysiology from the University of Waterloo, Ontario, Canada.

David Guyer
MEMBER, BOARD OF DIRECTORS

David Guyer, M.D., joined SV Life Sciences in 2006 and serves on the boards of portfolio companies Link Medicine, Lux Biosciences, NeoVista, Neurotech and Ophthotech as well as the public company Optos. David co-founded and served as CEO and director of Eyetech Pharmaceuticals Inc. for six years. He led Eyetech – a biopharmaceutical company that specialized in the development and commercialization of novel therapeutics to treat diseases of the eye – through private financing rounds totaling approximately $170 million, a $157 million initial public offering and a secondary financing. The company developed and gained FDA approval for Macugen, the first anti-VEGF treatment approved for macular degeneration. Eyetech partnered with Pfizer in a deal valued at over $750 million. OSI Pharmaceuticals subsequently acquired Eyetech in a deal valued at $935 million. Prior to founding Eyetech, Dr. Guyer was professor and chairman of the department of ophthalmology at the NYU School of Medicine. Dr. Guyer holds a bachelor of science from Yale College and a medical degree from Johns Hopkins Medical School.

Bruce Peacock
MEMBER, BOARD OF DIRECTORS

Bruce Peacock has served as a member of our board of directors since March 2015. Mr. Peacock served as Chief Financial and Business Officer of Ophthotech Corporation from August 2013 to September 2014 and served as its Chief Business Officer from September 2010 to August 2013.

From April 2008 to February 2011, Mr. Peacock served as President, Chief Executive Officer and co-Chairman of the board of directors of Alba Therapeutics where he continues to serve as co-Chairman of the board of directors.  Additionally, Mr. Peacock has served as a venture partner of SV Life Sciences Advisors, LLC since 2006.  Previously Mr. Peacock served as the Chief Executive Officer and Director of The Little Clinic; President, Chief Executive Officer and Director of Adolor Corp. (NASDAQ: ADLR) (acquired by Cubist Pharmaceuticals, Inc. (NASDAQ: CBST)); President, Chief Executive Officer and Director of Orthovita, Inc. (acquired by Stryker Corporation); Executive Vice President, Chief Operating Officer and Director of Cephalon, Inc. (acquired by Teva Pharmaceutical Industries Ltd.); and as Chief Financial Officer of Centocor, Inc. (acquired by Johnson & Johnson (NYSE: JNJ).

Mike Ross
MEMBER, BOARD OF DIRECTORS

Mike Ross’ career spans over 15 years in venture capital, which followed 21 years in senior operating executive roles for leading biotechnology companies. He joined SV Health Investors as a Venture Partner in 2001 and became a Managing Partner in 2002.

Mike was the tenth employee at Genentech, where he worked for 13 years. He served as Genentech team leader for Humulin® (human insulin-Lilly), Roferon® (Interferon alpha -Roche), Protropin® (hGH), Vice President of Development during the development of Activase®, Nutropin® and Pulmozyme®. He then started Genentech’s protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. Mike was the Founding CEO of Arris Pharmaceutical, MetaXen, ExSAR and CyThera (now Viacyte). He was also Managing Partner in Didyma, LLC, a biotechnology management consulting firm. Mike served on the boards of Carta Proteomics, Epimmune, Genencor, MetaXen, and Xenova.

Mike holds an AB from Dartmouth College, a PhD in Chemistry from Caltech, and a Post-Doctoral Fellowship in Molecular Biology from Harvard.

Kevin Starr
MEMBER, BOARD OF DIRECTORS

Kevin Starr is a proven operational leader with over 25 years’ experience building and operating leading biotech companies. Mr. Starr co-founded Third Rock Ventures in 2007 and focuses on the formation, development and business strategy of its portfolio companies as well as actively identifying and evaluating new investments. He also assumes active leadership roles in Third Rock portfolio companies. Prior to Third Rock Ventures, Mr. Starr was chief operating officer and chief financial officer at Millennium Pharmaceuticals, where he led efforts to raise billions of dollars in capital through strategic alliances and public financing and drove growth through company expansion and mergers and acquisitions. Earlier in his career, he served in various executive roles at Millennium BioTherapeutics, Biogen and Digital Equipment Corporation. Mr. Starr holds a master of science in corporate finance from Boston College and a bachelor of arts in mathematics and business from Colby College. He is a board member of Alnylam Pharmaceuticals and also serves on the board of directors for Afferent Pharmaceuticals, Agios Pharmaceuticals and Zafgen, Inc.

Paul Chaney
MEMBER, BOARD OF DIRECTORS

Paul Chaney is president and CEO of PanOptica and has nearly 30 years of experience in the pharmaceutical industry. He led the US and later global team that were responsible for Xalatan, the most widely prescribed treatment for elevated intraocular pressure (glaucoma) and the first pharmacotherapy for neovascular AMD.

Prior to co-founding PanOptica, Paul was executive vice president of OSI Pharmaceuticals and president of (OSI) Eyetech, OSI’s eyecare subsidiary. He joined Eyetech Pharmaceuticals as chief operating officer in 2003, where he led the team that introduced the first injectable anti-VEGF biologic treatment for treatment of wet-AMD.

Paul held a variety of senior management positions at Pharmacia Corporation, including vice president of the Global Ophthalmology Business and vice president of Global Pharmaceutical Ophthalmology. He began his career as a sales representative for The Upjohn Company in 1980. Paul earned a dual degree in Biological Sciences and English from the University of Delaware.